Nipple Discharge of CA15-3, CA125, CEA and TSGF as a  New Biomarker Panel for Breast Cancer

Wang, Gangping; Qin, Yan; Zhang, Junxi; Zhao, Jinhui; Liang, Yun-Ai; Zhang, Zuo‐Feng; Qin, Meihua; Sun, Yanqing

doi:10.3390/ijms15069546

Cited by 57 publications

(43 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The levels of the four biomarkers in nipple discharge were significantly higher than those in the serum (P<0.01). Furthermore, our previous research shown CA15-3, TSGF, CA125 and CEA also had a certain clinical signifcance in the early diagnosis of tumors [2,4]. In this study, the sensitivity of the four serum tumor markes in combination in diagnosis of breast cancer was only 69.77%, in contrast, the dynamic combined detection both in discharge and serum was 97.67%, and the negative predictive value was 99.03%.…”

Section: International Conference On Mechanical Science and Engineerimentioning

confidence: 49%

“…Abnormal nipple discharge is most commonly caused by benign conditions like intraductal papillomas, duct ectasia, papillomatosis, mastitis, fibrocystic changes [6][7][8][9]. The incidence of breast cancer in patients presenting with abnormal nipple discharge is between 5% to 21% [2,3,10]. A majority of patients with breast cancer who manifest with isolated nipple discharge have an early stage disease associated with ductal carcinoma in situ.…”

Section: Discussionmentioning

confidence: 99%

“…Majority of nipple discharge comes forth spontaneously and has a pathological outcome. It locates in or originates from mammary ducts and generally harbors a benign or malignant breast tumor [2][3][4][5]. Abnormal nipple discharge is most commonly caused by benign conditions like intraductal papillomas, duct ectasia, papillomatosis, mastitis, fibrocystic changes [6][7][8][9].…”

Section: Discussionmentioning

confidence: 99%

“…It is the most common cancer among women both in developed and developing countries. Nipple discharge is a relatively common breast complaint accounting for up to 5% of which women seek medical advice [2][3][4]. Majority of nipple discharge comes forth spontaneously and has a pathological outcome.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical Value of Nipple Discharge and Serum Markers of Breast Cancer

Liang¹,

Mou²,

Zhang³

et al. 2016

Proceedings of the 2015 International Conference on Mechanical Science and Engineering

View full text Add to dashboard Cite

Abstract. Serum biomarkers are of diagnostic value and can be used for follow-up and prognostic factors. However, serum protein biomarkers show limited diagnostic sensitivity and specificity in stand-alone assays breast cancer because their levels refect tumor burden. In this study, we reviewed the levels of CA15-3, TSGF, CA125 and CEA both in nipple discharge and serum in 179 cases of breast lesions to assess the clinical value of nipple discharge and serum tumor markers in diagnosis, follow-up and prognostic in breast cancer. Our results indicate that the nipple discharge and serum levels of CA15-3, TSGF, CA125 and CEA in breast carcinomas patients were significantly higher than those in the benign disease (P<0.01). Aditionally, The levels of the four tumor markers in nipple discharge were significantly higher than in the serum (P<0.01). The levels of the four biomarkers in nipple discharge had positive correlation with histological grade, clinical stage, the Ki-67 index, expression of VEGF and HER-2/neu, lymphnode metastas and tumor recurrence (P<0.05, respectively), and negative correlation with the level of ER or PR (P<0.05, respectively). The sensitivity of the four serum tumor markes in combination was only 69.77%, in contrast, the combined detection both in discharge and serum was 97.67%, and the negative predictive value was 99.03%. The sensitivity of combined detection both in nipple discharge and serum were significantly higher than other detection (P<0.05). The four tumor markers in nipple discharge are as novel biomarker in dignosis and judging the prognosis of breast cancer. The dynamic combined detection of the four tumor markers both in nipple discharge and serum are helpful to the stratification of preoperative patients and benefit to better prewarning markers for monitoring their recurrence and metastasis of tumors in clinic, but cannot increase the sensitivity of judging the patients with early breast cancer.

show abstract

Section: International Conference On Mechanical Science and Engineerimentioning

confidence: 49%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Value of Nipple Discharge and Serum Markers of Breast Cancer

Liang¹,

Mou²,

Zhang³

et al. 2016

Proceedings of the 2015 International Conference on Mechanical Science and Engineering

View full text Add to dashboard Cite

show abstract

“…It was found as the first breast cancer‐associated antigen in 1984 7. After decades of experimental research on it, investigators had found that CA15‐3 could be used as diagnostic and prognostic factor and could also provide valuable information during follow‐up 8, 9, 10, 11. Thus, measurement of CA15‐3 is significant for breast cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a newly developed quantitative determination kit for tumor marker CA15‐3 with chemiluminescent assay

Liu³

et al. 2017

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundTumor marker carbohydrate antigen 15‐3 (CA15‐3) is used as a biomarker to aid to diagnose and monitor the prognosis of breast cancer patients. A new quantitative determination kit for CA15‐3 with chemiluminescent assay was developed by Xiamen InnoDx Biotech Co., Ltd, China. Therefore, we conducted the report to evaluate the performance of the kit.MethodsAccording to the “Guiding principles on performance analysis of diagnostic reagents in vitro”, the calibration curve, limit of detection, reportable range, accuracy, precision, anti‐interference capability, cross‐reaction and comparison by measuring EDTA plasma and serum were carried out. In addition, the kit was performed in parallel to electrochemiluminescence immunoassay kit (Roche) to analyze the correlation between the two kits.ResultsRegression equation of calibration curve of the kit was Y=0.7914X+4.1032 (R2=.990). Limit of detection was 0.0347 U/mL. The reportable range was 0.5‐2400 U/mL. Recovery ratio was 100.0%‐104.8%. Coefficient of variations (CVs) of within‐run and between‐run were 4.8%‐7.6% and 5.8%‐7.4% respectively. No remarkable interferences (all Bias% were less than ±10%) were detected when samples contained hemoglobin ≤183.8 μmol/L, bilirubin ≤340 μmol/L, triglyceride ≤18.1 mmol/L, or rheumatoid factor ≤400 U/mL. No cross‐reaction was present in the kit. Moreover, compared with the results from electrochemiluminescence immunoassay kit (Roche) in 345 serum samples, there was a satisfied correlation coefficient of 0.977 (P<.01), and the kit was simultaneously fit for the detection of EDTA plasma and serum samples.ConclusionThe new kit validated satisfactorily, and it can be used for detecting CA15‐3 in clinical practice.

show abstract

Advanced Functional Structure‐Based Sensing and Imaging Strategies for Cancer Detection: Possibilities, Opportunities, Challenges, and Prospects

Kumar

Kukkar

Hashemi

et al. 2019

Adv Funct Materials

View full text Add to dashboard Cite

Cancer is the second most common cause of death in the world. The principal limitations thus far encountered in the clinical practice of probing cancer are diverse and include low sensitivity, time consumption, bulkiness, and cost. In this respect, nanomaterial (NM)-based sensing techniques are recognized as a superior alternative to efficiently resolve such limitations. A better understanding of NM-based sensing platforms is thus important so that these novel avenues can easily be explored for clinical applications. These platforms have the merits of high sensitivity, high specificity, rapid response, and easy-to-read signals. This review offers a comprehensive survey of NM-based advanced cancer-sensing techniques and will help the scientific community establish optimum sensing strategies based on an accurate assessment of the interactions between cancer biomarkers and NM-based platforms.but are not limited to, carcinoma, sarcoma, leukemia, lymphoma, non-Hodgkin lymphoma, myeloma, central nervous system cancer, lung and bronchus cancer, colon cancer, rectum cancer, prostate cancer, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, pancreatic cancer, liver cancer, and thyroid cancers. [1] Moreover, the most commonly occurring cancers tend to differ by common criteria like sex and age. For example, men are at risk for prostate, lung, and colorectal cancer, women are at risk for breast, lung and colorectal cancer, and children are at risk for leukemia, brain tumors, and lymphoma. The severity of the cancer depends upon the development level or staging of the disease. [2] Likewise, the type of treatment required to treat the cancer is determined by the staging of the disease.The more severe condition of cancer is metastasis, i.e., the uncontrolled growth of cells that invade surrounding tissues. The metastasis condition of cancer can affect any organ of the body. [3] As per the WHO 2010 report on cancer, the lives of 30% patients could have been saved if the cancer was diagnosed earlier. The detection of cancer is not easy because the immune system does not necessarily consider cancerous cells as foreign bodies. However, a few changes (such as altered biomarker levels and the presence of cancerous cells in biological fluids) can be detected. [4] In general, cancer biomarkers are overexpressed proteins present in blood/serum and at the cancer cell surface. The accurate and efficient detection of these biomarkers can be useful for cancer detection. The major problem with biomarkers is their low level in the body during the earlier stages of cancer. Hence, an efficient sensor/device capable of detecting these molecules even at very low levels, if developed, could help the clinician efficiently diagnose cancer cells in the human body.The sensing techniques presently used by clinicians suffer from several limitations; specifically, they are time consuming, bulky, have low sensitivity, and are expensive. Nanomaterial (NM)-based techniques have become an important alternative to the laborious conventional...

show abstract

Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer

Cited by 57 publications

References 27 publications

Clinical Value of Nipple Discharge and Serum Markers of Breast Cancer

Clinical Value of Nipple Discharge and Serum Markers of Breast Cancer

Evaluation of a newly developed quantitative determination kit for tumor marker CA15‐3 with chemiluminescent assay

Advanced Functional Structure‐Based Sensing and Imaging Strategies for Cancer Detection: Possibilities, Opportunities, Challenges, and Prospects

Contact Info

Product

Resources

About